Heat Biologics Inc (NASDAQ:HTBX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Thursday. The firm presently has a $0.75 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price would suggest a potential upside of 6.93% from the company’s previous close. According […]